362 related articles for article (PubMed ID: 20403244)
1. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer].
Zhang P; Xu BH; Ma F; Li Q
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
3. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer].
Wang YJ; Wang N; Wang B; Qin WX; Xue CY
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
10. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
11. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
Mehta RS
J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
[No Abstract] [Full Text] [Related]
12. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
Ma JG; Wang NJ; Yu WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancers: unique clinical presentations and outcomes.
Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
[TBL] [Abstract][Full Text] [Related]
16. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1095-101. PubMed ID: 20638197
[TBL] [Abstract][Full Text] [Related]
18. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
19. [Postmastectomy locoregional recurrence and survival in early stage breast cancer patients with one to three axillary lymph node metastases].
Zhang YJ; Sun GQ; Chen J; Chen J; Huang XB; Lin HX; Hu YH; Liu MZ; Yang MT; Guan XX
Ai Zheng; 2009 Apr; 28(4):395-401. PubMed ID: 19622300
[TBL] [Abstract][Full Text] [Related]
20. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
